INTRODUCTION
Platelet aggregation is a key mechanism for normal hemostasis limiting blood loss after tissue trauma 1 , but at sites of atherosclerotic plaque rupture it may also lead to arterial occlusion and embolism causing myocardial infarction or stroke 2, 3 . Therefore, the inhibition of platelet function has become an important strategy for prevention and treatment of ischemic cardio-and cerebrovascular events 4 .
Platelet plug formation is a multi-step process that involves the concerted action of multiple membrane receptors and intracellular signaling pathways. Under conditions of elevated shear as found in arterioles or stenosed arteries, the rapid on-set of interaction between glycoprotein (GP) Ib-V-IX and von Willebrand factor (vWF) immobilized on collagen is crucial for the initial tethering of flowing platelets 5 . This interaction is, however, not stable and must be followed by the stimulation of platelet receptors that mediate cellular activation resulting in calcium mobilization, shape change, upregulation of integrin affinity, release of secondary agonists and coagulant activity of the cells 2, 6, 7 . Two major classes of activatory receptors exist in platelets. Soluble agonists such as thrombin, adenosine diphosphate (ADP) and thromboxane A2 (TxA 2 ) stimulate receptors that couple to heterotrimeric G proteins (G q , G 12/13 , G i/z ) and activate downstream effectors 8 . The other pathway is similar to that used by immunoreceptors and involves sequential activation of Src and Syk family tyrosine kinases which orchestrate a downstream signaling cascade that is regulated through the interaction of several adaptor proteins, including LAT and SLP-76 and leads to activation of effector enzymes, including phosphatidylinositol-3-kinases and phospholipase (PL) Cγ2. This pathway is triggered by the major activatory platelet collagen receptor, GPVI, which signals via the immunoreceptor tyrosine-based activation motif (ITAM)-bearing Fc receptor γ-chain 9, 10 or by CLEC-2, where signaling is initiated by tyrosine phosphorylation of a single YXXL motif in its cytoplasmic tail 11, 12 .
CLEC-2 is a C-type lectin-like type II transmembrane receptor that was originally identified in immune cells 13, 14 and only recently revealed to be expressed in platelets where it serves as For personal use only. on October 31, 2017. by guest www.bloodjournal.org From the receptor for rhodocytin, a very potent platelet activating protein isolated from the Malayan pit viper Calloselasma rhodostoma 11 . Based on the observation that rhodocytin-induced platelet activation shares some similarities with the responses elicited by collagen, integrin α2β1 and GPIbα were initially proposed to be targeted by the protein [15] [16] [17] but this was shortly later disproven by the finding that rhodocytin fully activated platelets in the absence of these receptors 18 . Due to its impressive activatory potential, it has been speculated that CLEC-2 might become a target for antithrombotic agents 19 , although its physiological function has remained elusive.
Recent data indicate that CLEC-2 might be involved in hematogenous tumor metastasis as the receptor mediates tumor cell-induced platelet activation, a process known to significantly promote tumor cell spreading 20, 21 by interacting with the type I transmembrane sialomucinlike glycoprotein podoplanin (aggrus) on the tumor cell surface 22 . In addition, CLEC-2 has been identified as an attachment factor for human immunodeficiency virus type 1 (HIV-1) that mediates the capture and transfer of infectious HIV-1 by platelets, making it a potentially important determinant of virus spread in infected humans 23 . In addition, the receptor has been reported to play a role in phagocytic activity of neutrophils 24 . However, the importance of CLEC-2 for platelet activation during hemostasis and in the course of thrombotic events is not defined 19 .
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MATERIALS AND METHODS
Mice. Specific-pathogen-free male NMRI mice 4 to 10 weeks of age were obtained from Harlan Winkelmann (Borchen, Germany) and kept in our animal facilities. Animal studies were approved by the district government of Lower Franconia (Bezirksregierung Unterfranken).
Chemicals and antibodies. Anesthetic drugs: medetomidine (Pfizer, Karlsruhe, Germany), midazolam (Roche Pharma AG, Grenzach-Wyhlen, Germany), fentanyl (Janssen-Cilag GmbH, Neuss, Germany) and antagonists: atipamezol (Pfizer, Karlsruhe, Germany), flumazenil and naloxon (both from Delta Select GmbH, Dreieich, Germany) were used according to the regulation of the local authorities. ADP (Sigma, Deisenhofen, Germany), U46619 (Alexis Biochemicals, San Diego, USA), thrombin (Roche Diagnostics, Mannheim, Germany), and collagen (Kollagenreagents Horm, Nycomed, Munich, Germany) were purchased. Mouse α -rat IgG (Dianova, Hamburg, Germany) and α -rat FITC (DAKOCytomation, Denmark) were purchased. Rhodocytin was isolated as described 18 .
Monoclonal antibodies conjugated to fluorescein isothiocyanate (FITC) or phycoerythrin (PE), or DyLight-488 were from Emfret Analytics (Würzburg, Germany). The JON/A-PE antibody preferentially binds to the high affinity conformation of mouse αIIbβ3 integrin 25 .
Production of monoclonal antibodies (mAbs). Female Wistar rats, 6-8 weeks of age, were immunized repeatedly with mouse platelets. The rat spleen cells were then fused with mouse myeloma cells (Ag14.653) and hybridomas were selected in HAT medium. Hybridomas secreting mAbs directed against platelet receptors were identified by flow cytometry. Briefly, a 1:1 mixture of resting and thrombin-activated platelets (10 6 cells) was incubated with 100 µL supernatant for 30 min at room temperature, washed with PBS (1,300g, 10 min) and stained with FITC-labeled rabbit anti-rat Ig for 15 min. The samples were analyzed on a FACScalibur (Becton Dickinson, Heidelberg, Germany) in the set up mode. Platelets were For personal use only. on October 31, 2017. by guest www.bloodjournal.org From 6 gated by FSC/SSC-characteristics. Positive hybridomas were subcloned twice prior to large scale production.
Modification of antibodies. Fab fragments from INU1 were generated by 12-hour incubation of 10 mg/mL mAb with immobilized papain (Pierce), and the preparations were then applied to an immobilized protein A column followed by an immobilized protein G column (Biorad, Munich, Germany and GEHealthcare, Sweden) to remove Fc fragments and any undigested IgG. The purity of the Fab fragments was checked by sodium dodecyl sulphatepolyacrylamide gel electrophoresis (SDS-PAGE). Measurement of ATP release. Washed platelets were adjusted to a concentration of 0.4 x 10 6 /µl. Platelets were activated with the indicated agonists for 2 min at 37°C under stirring conditions (1000 rpm). Following activation, EDTA (3 mM final concentration) and formaldehyde (0.1% final concentration) were added and platelets were fixed for 2 h. The platelets were then centrifuged for 1 min at 13,000 rpm and 100 µl supernatant were added to 100 µl absolute ethanol. Samples were stored at -20°C until measuring. Levels of ATP in 12.5 µl sample were quantified using a bioluminescence assay kit (Roche Diagnostics, Germany) and a Fluostar Optima luminometer (BMG Lab technologies, Germany).
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From Adhesion under flow conditions. Rectangular coverslips (24 x 60 mm) were coated with 0.2 mg/ml fibrillar type I collagen (Nycomed, Munich, Germany) for 1 h at 37°C and blocked with 1% BSA. Heparinized whole blood was labeled with a Dylight-488 conjugated anti-GPIX Ig derivative at 0.2 µg/ml and perfusion was performed as described 27 . Image analysis was performed off-line using Metavue software (Visitron, Munich, Germany). Thrombus formation was expressed as the mean percentage of total area covered by thrombi, and as the mean integrated fluorescence intensity per mm 2 as described 28 . For flow adhesion studies under non-anticoagulated conditions, blood was taken into 1/10 vol. 129 mM trisodium citrate and co-infused with CaCl 2 /MgCl 2 buffer as described 29 .
Bleeding time. Mice were anesthetized and a 1 mm segment of the tail tip was removed with a scalpel. Tail bleeding was monitored by gently absorbing blood with filter paper at 20 second intervals, without making contact with the wound site. When no blood was observed on the paper, bleeding was determined to have ceased. Experiments were stopped after 20 minutes. For personal use only. on October 31, 2017. by guest www.bloodjournal.org From Statistics. Results from at least three experiments per group are presented as mean ± SD.
Intravital microscopy of thrombus formation in

Differences between control and INU1-treated groups were assessed by the Mann-Whitney
U-test. P-values < 0.05 were considered statistically significant.
RESULTS
A new rat monoclonal antibody (mAb) against mouse CLEC-2 (INU1, rat IgG1) was generated. INU1 bound to mouse platelets ( Fig. 1A) and precipitated a protein of an apparent molecular weight of approximately 32-38 kD under reducing and nonreducing conditions ( Fig.   1B ), demonstrating that the apparent molecular weight of mouse CLEC-2 is similar to its human homologue 11, 30 . The antigenic specificity of INU1 for CLEC-2 was confirmed by ELISA where it bound to the extracellular domain of mouse CLEC-2 fused to the Fc-portion of human IgG1 (mCLEC-2-Fc), but not to mGPVI-Fc 26 . In contrast, the anti-mouse GPVI antibody, JAQ1 31 , bound to mGPVI-Fc, but not to mCLEC-2-Fc ( Fig. 1C ). INU1 did not recognize CLEC-2 in Western blot analysis of platelet lysates, indicating that the antibody binds to a three-dimensional epitope on the receptor that is lost under the denaturing conditions during SDS-PAGE (not shown).
In line with previous observations with (polyclonal) anti-CLEC-2 antibodies in human platelets 11 , INU1 induced aggregation of mouse platelets (Fig. 1D ). This response occurred in a dose-dependent manner evident as a decrease in the delay before the onset of aggegation rather than an increase in the maximal aggregation response. A similar effect can be seen with rhodocytin on human platelets 11 and mouse platelets (not shown). INU1induced activation was associated with changes in the tyrosine phosphorylation patterns that were comparable to those induced by rhodocytin ( Fig. 1E) .
In contrast to INU1-IgG, monovalent Fab fragments of the antibody did not induce aggregation at concentrations up to 20 µg/ml ( Fig. 2A ), suggesting that receptor dimerization /clustering is a critical prerequisite for CLEC-2-mediated platelet activation. This was confirmed by crosslinking of the bound Fab fragments by a secondary antibody (rabbit antirat IgG) which induced robust aggregation ( Fig. 2A ). INU1-Fab (20 µg/ml) had no effect on the aggregation response to the stable TxA 2 analog U46619, the GPVI agonist convulxin (CVX) or thrombin, but ADP-induced aggregation was consistently increased in the presence of the antibody fragment (83.53 ± 4.57% vs. 58.76 ± 5.12% in control) ( Fig. 2B) . In contrast,
INU1-Fab had a significant inhibitory effect on rhodocytin-induced platelet aggregation at low and intermediate agonist concentrations (visible as a delay in the onset of aggregation)
which was, however, overcome at high rhodocytin concentrations (Fig. 2C) . These results suggested that INU1 binds to an epitope on CLEC-2 that is at least partially overlapping with the rhodocytin binding site on the receptor.
INU1-induced loss of CLEC-2 in circulating platelets
To study the effect of INU1 on platelets in vivo, mice received 2 µg/g body weight of the antibody i.v. and circulating platelets were studied ex vivo at different time points after injection. INU1 treatment induced transient thrombocytopenia with a maximum drop of platelet counts >85% on day 1 and a return to normal or in some animals slightly increased platelet counts after 3-4 days where they remained for at least 6 more days (Fig. 3A) . This effect was not Fc-dependent or caused by antibody-induced receptor dimerization as it was also seen with Fab fragments of INU1 (2 µg/g body weight) ( Fig. 3A ). INU1 treated mice did not develop spontaneous bleeding for at least three weeks (not shown). Free To study the functional consequences of CLEC-2 deficiency in more detail and to test whether a prolonged loss of the receptor can be achieved, mice received 8 µg/g body weight INU1 i.v.. In these animals, free INU1 IgG was detectable by ELISA for 5-8 days (data not shown). The resulting thrombocytopenia and the kinetics of CLEC-2 loss were comparable to the effects caused by 2 µg/g body weight (Fig. 3A) but CLEC-2 was not detectable on the surface of the cells for at least 6 days ( Fig. 3C, D) . Immunoprecipitation experiments performed on day 5 after antibody injection confirmed the complete loss of CLEC-2 whereas other receptors such as GPVI were not affected (Fig. 3E ). This was also shown by flow cytometric analysis of basal surface expression levels of GPVI, GPIb-V-IX, CD9 and integrins αIIbβ3 and α2β1 on day 5 (table 1). Hematocrits and white blood cell counts were not significantly different between control and INU1-treated mice (table 1).
Standard aggregometry revealed that platelets from mice on day 5 after INU1 injection (8 µg/g body weight) were completely resistant to activation with rhodocytin at any concentration tested (up to 10 µg/ml) whereas responses to ADP, U46619, CVX, collagen and thrombin were normal (Fig. 4A ). Flow cytometric analyses of integrin αIIbβ3 activation and degranulation-dependent P-selectin exposure confirmed that INU1-induced CLEC-2 deficiency had no significant effect on platelet activation by ADP, U46619, CVX or thrombin, whereas responses to rhodocytin were blunted (Fig. 4B ). Furthermore, thrombin-and CRPinduced ATP release from dense granules was not significantly different in platelets from INU1-treated mice compared to controls, confirming that the antibody treatment does not have a general effect on the degranulation machinery ( Fig. 4C ).
On day 10 after INU1 injection, CLEC-2 expression ( Fig. 3D ) and rhodocytin-induced responses (not shown) were fully restored in all tested animals. Together, these results demonstrated that INU1-induced CLEC-2 deficiency very specifically abolished one activation pathway in platelets while leaving other ones fully intact.
CLEC-2 is required for stable thrombus formation under flow
At sites of vascular injury, the signals generated by multiple platelet receptor-ligand interactions are integrated to ensure efficient platelet attachment and thrombus formation under flow conditions 7 . A possible function of CLEC-2 in this process has not been assessed to date. Therefore, we analyzed the ability of CLEC-2-deficient platelets to form thrombi on collagen-coated surfaces in a whole blood perfusion system 27 . Under high shear conditions
(1,700 s -1 ), control platelets adhered to collagen fibers and formed aggregates within 2 min that consistently grew into large thrombi by the end of the perfusion period of 4 min (suppl. video 1). In marked contrast, while CLEC-2-deficient platelets exhibited unaltered adhesion to collagen under flow ( Fig. 5A) , the subsequent formation of three-dimensional aggregates was severely impaired (Fig. 5B ). During the entire perfusion time, adherent platelets recruited numerous new platelets from the blood flow, but these were consistently unable to firmly attach and were released after a few seconds (suppl. video 2). As a consequence, the surface area covered by platelets and the total thrombus volume at the end of the experiment were reduced by 36% and 82%, respectively (Fig. 5B ). Similar results were obtained at intermediate shear rates (1,000 s -1 , data not shown). These findings demonstrated that CLEC-2-dependent processes are essential for stable aggregate formation under flow, whereas the receptor is not required for the adhesion process on collagen.
To test whether the thrombus instability was based on impaired platelet activation, we performed flow adhesion studies under non-anticoagulated conditions to allow thrombin generation. Under these conditions, both control and CLEC-2-deficient platelets formed large stable thrombi (Fig. 5C ), indicating that in the presence of high amounts of thrombin, platelet activation through CLEC-2 is not essential for thrombus stabilization in this flow dependent system. Similarly, coinfusion of ADP (10 µM) and U46619 (1 µM) into anticoagulated blood shortly before entering the flow chamber likewise resulted in the formation of large and stable aggregates in both control and CLEC-2-deficient blood (data not shown). Together, these data indicate that CLEC-2 functions as an activatory receptor in platelets that is required for 
Increased bleeding times and defective arterial thrombus formation in CLEC-2deficient mice
As platelet aggregation is a major pathomechanism in acute ischemic cardiovascular events, we studied the effects of CLEC-2 deficiency on pathologic occlusive thrombus formation by in vivo fluorescence microscopy following ferric chloride-induced mesenteric arteriole injury.
In all control mice, the formation of small aggregates was observed ~5-7 min after injury, with progression to complete vessel occlusion within 20 min (mean occlusion time: 16.4 ± 2.2 min) ( Fig. 6A-C) . In contrast, while initial adhesion and formation of small aggregates occurred with similar kinetics in CLEC-2-deficient mice (6.9 ± 1.5 min vs. 6.5 ± 1.5 min in control, p>0.05) progression to stable large thrombi was almost completely abrogated. This defect was to a great extent caused by the release of individual platelets from the thrombus surface but also embolization of small thrombus fragments was observed (suppl. videos 3 and 4). Consequently, blood flow was maintained throughout the 40 min observation period in all CLEC-2-deficient mice, revealing a crucial role for CLEC-2 during occlusive thrombus formation.
To test whether the INU1-induced CLEC-2 deficiency has an impact on hemostasis, we measured tail bleeding times. While bleeding stopped in all (22/22) control mice during the 20 min observation period (mean bleeding time: 6.1 ± 3.9 min), bleeding times were increased in INU1-treated mice, with 8 of 24 (33.3%) mice bleeding for >20 min and a mean bleeding time of 10.8 ± 6.0 min for the other animals (p<0.05) (Fig. 6D) . These results show that CLEC-2 plays a significant role for normal hemostasis.
DISCUSSION
Here we have demonstrated that the recently identified platelet membrane glycoprotein CLEC-2 plays a fundamental role in thrombus formation in hemostasis and thrombosis.
Despite the previously known activatory potential of the receptor 11, 18 these results were unanticipated as the only known endogenous ligand of the receptor, podoplanin, is mainly expressed in epithelial and tumor cells and can therefore not account for CLEC-2 activation at sites of vascular injury 19, 22 .
Thrombus formation under flow conditions in vitro and also in vivo is severely defective in the antibody-induced absence of CLEC-2. This strongly suggests that the ligand(s) of the receptor are present in plasma or they may be presented on the surface of or released by (activated) platelets. CLEC-2 ligands could also be present at the injured vessel wall but this may not be crucial for attachment of the first layer of platelets as indicated by unaltered formation of small aggregates at sites of injury in CLEC-2-deficient mice in vivo (Fig. 6 ). This notion is also supported by the observation that CLEC-2-deficient platelets can attach normally to collagen under high shear flow conditions (Fig. 5A, suppl. video 2) , a process known to be driven mainly by GPIb, GPVI and integrins α2β1 and αIIbβ3 6, 7, 32 . Rather, CLEC-2-dependent signaling appears to be required for establishing (activation-dependent) stable platelet-platelet contacts under flow conditions as revealed by the defective transition of newly recruited platelets to firm adhesion on the surface of collagen-adherent platelets (suppl. video 2). This process also appears to be crucial for stable thrombus formation in vivo as revealed by the constant release of individual platelets and frequent embolization of small aggregates from the surface of the developing thrombus in CLEC-2-deficient mice (suppl. video 4). As a consequence, no occlusion was seen in these animals, thus identifying CLEC-2 as an interesting potential target for antithrombotic therapy.
We show that CLEC-2 can indeed be specifically targeted and functionally inactivated by the antibody INU1 in vivo. Remarkably, this in vivo inhibition by far exceeded the inhibitory potential of the antibody in vitro as it was not based on pure blockade of the receptor. Rather, For personal use only. on October 31, 2017. by guest www.bloodjournal.org From INU1 induced the irreversible loss of CLEC-2 from circulating platelets, a process previously only reported for GPVI in mouse and human platelets 33, 34 . The complete loss of functional CLEC-2 in platelets of INU1-treated mice was confirmed by different approaches. Firstly, these platelets were completely refractory to activation with rhodocytin ( Fig. 3, 4) whereas Fab fragments of the antibody only had a limited inhibitory potential in vitro (Fig. 2) .
Secondly, flow cytometric analyses confirmed the complete loss of CLEC-2 from the surface of circulating platelets within 24 hours after INU1 injection and thirdly, immunoprecipitation confirmed a prolonged absence of the protein for at least 5 days (Fig. 3) .
We were not able to identify the route of CLEC-2 downregulation, but mClec-2A expressed in HEK293T cells has been shown to be proteolytically cleaved to produce a soluble extracellular fragment 35 . This indicates that the loss of CLEC-2 could occur through ectodomain shedding, but also internalization/degradation might contribute to this process.
We have previously demonstrated that antibody-induced downregulation of GPVI can occur through both of these routes and that these are regulated by diverging signaling pathways downstream of the receptor in vivo 36 . These are, however, difficult to assess as neither GPVI 33, 34, 37, 38 nor CLEC-2 (not shown) can be downregulated in murine platelets by antibodies in vitro. This indicates that additional signals or a certain environment may be required for this process to occur that is absent in our in vitro assays. It is clear, however, that the Fc part of the antibody or receptor dimerization is not required for CLEC-2 downregulation in vivo as Fab fragments are equally efficient compared to the intact IgG. indicating that the antibody may also affect megakaryocytes. Indeed, INU1 is detectable on megakaryocytes in spleen and bone marrow 90 min after antibody injection (data not shown) and preliminary data indicate that a second injection of INU1 on day 6 has no effect on circulating (CLEC-2-deficient) platelets but prolongs the absence of CLEC-2 (data not shown). Similar effects can be seen in JAQ1-treated mice where the "knock-out-like" phenotype does, however, last for two weeks upon a single injection of 100 µg antibody per mouse 33, 37, 40 . This indicates that INU1 may only affect those megakaryocytes which produce the very next generation of platelets but further studies will be required to test this hypothesis.
Irrespective of the underlying mechanism, platelets from INU1-treated mice showed a specific loss of CLEC-2 activity which translated into a severe defect in thrombus growth and stabilization under flow conditions in vitro and in vivo (Fig. 5, 6 ). Similarly impaired aggregate stabilization can also be seen in mice lacking functional stromal interaction molecule 1 (STIM1), an essential regulator of Ca 2+ signaling in platelets 28, 41 . Such platelets display a selective defect in ITAM/YXXL-dependent activation, indicating that this signaling route is not only of importance for platelet activation on the ECM via GPVI but also for thrombus growth where collagen/GPVI does not play a role 28, 41 . In the light of the data reported here it is tempting to speculate that the thrombus instability observed in the absence of STIM1 may to a great extent be caused by impaired CLEC-2 signaling. Similarly, the thrombus formation defects seen in mice lacking critical molecules of ITAM-signaling pathway such as LAT 42 or PLCγ2 43 might also be related to defective CLEC-2 signaling.
Our in vivo studies show that treatment of mice with an antibody against CLEC-2 induces a specific CLEC-2 deficiency in platelets for a prolonged period of time which is associated with profound protection of the animals from occlusive thrombus formation. On the other For personal use only. on October 31, 2017. by guest www.bloodjournal.org From hand, lack of CLEC-2 is associated with a significant increase in bleeding times (Fig. 6D ), but compared to bleeding time prolongations induced by integrin αIIbβ3 or GPIbα inhibition 44 the effect is moderate. The high variability in bleeding times most likely reflects a rather mild hemostatic defect based on thrombus instability at the site of the tail wound. Based on this assumption, one may speculate that the lack of CLEC-2 signaling is to a certain extent compensated by other mechanisms (ADP, TxA2, thrombin etc.) that may vary between individuals, for example because of slight differences in the injury. In line with this, a similar variability in tail bleeding times has previously been reported for other mouse lines with deficiencies in activatory platelet receptors, such as P2Y1 45 or the α2A adrenergic receptor 46 .
Although bleeding times do not allow reliable prediction of a potential bleeding risk 47 , one may speculate on the grounds of these results that anti-CLEC-2 therapy might be associated with a relatively low risk of clinical hemorrhage. CLEC-2-deficient humans have not been reported to date and it is not clear whether mutations in the CLEC-2 gene affect development in humans or mice. However, it can be anticipated that patients with an acquired CLEC-2 deficiency exist, caused by autoantibody-induced CLEC-2 clearing in platelets as previously reported for GPVI-deficiencies 34, 48 . The identification of such patients might help to define the role of CLEC-2 in the physiology of human platelets.
Taken together, we have demonstrated that CLEC-2 is an essential mediator of platelet activation in vitro and in vivo and that it represents an interesting antithrombotic target that can be functionally inactivated in vivo. These findings may serve as a basis for development of a new generation of powerful, yet safe, agents for prophylaxis and treatment of ischemic cardiovascular events. 
